FAYETTEVILLE, Ark. (KNWA/KFTA) — The FDA is issuing its strongest warning for a popular asthma and allergy drug.
The agency has announced it’s issuing a “boxed warning” for Singulair.
The new label will advise doctors to avoid prescribing the medication for mild symptoms especially those with hay fever.
The drug has carried a warning since 2008 about a link with an increased risk of depression, sleeping problems, and suicidal thoughts.
However, the FDA said a review of data last year shows the risks may outweigh the benefits in some patients.